Morbus Alzheimer (Latin Wikipedia)

Analysis of information sources in references of the Wikipedia article "Morbus Alzheimer" in Latin language version.

refsWebsite

Global rank Latin rank

22nih.gov

4^th place

12^th place

1stetoskop.info

low place

169^th place

1web.archive.org

1^st place

3^rd place

1frontiersin.org

4,679^th place

4,514^th place

frontiersin.org

Santiago J. A., Potashkin S. A. (Feb 2021). "The Impact of Disease Comorbidities in Alzheimer's Disease". Frontiers in ageing neuroscience

nih.gov

pubmed.ncbi.nlm.nih.gov

Bloom G. S. (Apr 2014). "Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis". JAMA neurology 71 (4): 505-8
Chen Y., Dang M., Zhang Z. (Iun 2021). "Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns". Molecular neurodegeneration 16 (1): 38
McKhann G. M., Knopman D. S., et al. (Mai 2011). "The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease". Alzheimer & dementia 7 (3): 263-9 .
Jack C. R. Jr., Bennett D. A. (Apr 2018). "NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease". Alzheimer & dementia 14 (4): 535-62 .
Tolar M., Abushakra S., Hey J. A., Porsteinsson A., Sabbagh M. (Aug 2020). "Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval". Alzheimer's research & therapy 12 (1): 95
Miziak B., .Błaszczyk B., Czuczwar S. L. (Mai 2021). "Some Candidate Drugs for Pharmacotherapy of Alzheimer's Disease". Pharmaceuticals 14 (5): 458
Mintun M. A., Lo A. C., Evans C. D., Wessels A. M., Ardayfio P. A., Andersen S. W., Shcherbinin S., Sparks J., Sims J. R., Brys M., Apostolova L. G., Salloway S. P., Skovronsky D. M. (Mar 2021). "Donanemab in Early Alzheimer's Disease". New England Journal of Medicine 384 (18): 1691-704
Sevigny J., Chiao P., Bussière T., Weinreb P. H., Williams L., Maier M., Dunstan R., Salloway S., Chen T., Ling Y., O'Gorman J., Qian F., Arastu M., Li M., Chollate S., Brennan M. S., Quintero-Monzon O., Scannevin R. H., Arnold H. M., Engber T., Rhodes K., Ferrero J., Hang Y., Mikulskis A., Grimm J., Hock C., Nitsch R. M., Sandrock A. (Sep 2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature 537 (7618): 50-6
Abushouk A. I., Elmaraezy A., Aglan A., Salama R., Fouda S., Fouda R., AlSafadi A. M. (Apr 2017). "Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials". BMC neurology 17 (1): 66
Klein G., Delmar P., Voyle N., Rehal S., Hofmann C., Abi-Saab D., Andjelkovic M., Ristic S., Wang G., Bateman R., Kerchner G. A., Baudler M., Fontoura P., Doody R. (Dec 2019). "Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis". Alzheimer's research & therapy 11 (1): 101
Toyn J. (Mai 2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert review of clinical pharmacology 8 (3): 267-9
Cirrito J. R., Wallace C. E., Yan P., Davis T. A., Gardiner W. D., Doherty B. M., King D., Yuede C. M., Lee J.-M., Sheline Y. I. (Nov 2020). "Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model". Neurolgy 95 (19): e2666-e2674
Sheline Y. I., Snider B. J., Beer J. C., Seok D., Fagan A. M., Suckow R. F., Lee J.-M., Waligorska T., Korecka M., Aselcioglu I., Morris J. C., Shaw L. M., Cirrito J. R. (2020). "Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial". Neurology 95 (19): e2658-e2665

ncbi.nlm.nih.gov

Knopman D. S., Petersen R. C., Jack C. R. Jr. (2019). "A brief history of "Alzheimer disease": Multiple meanings separated by a common name". Neurology 92 (22): 1053-9
Heneka M. T., Carson M. J., El Khoury J., et al. (2015). "Neuroinflammation in Alzheimer's Disease". The Lancet. Neurology 14 (4): 388-405 .
Lee S. H., Harold D., Nyholt D. R. et al. (2013). "Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis". Humam molecular genetics 22 (4): 832-41
Wolf A. B., Caselli R. J., Reiman E. M., Valla J. (2013). "APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease". Neurobiology of aging 34 (4): 1007-17 .
Hashimoto M., Rockenstein E., Crews L., Masliah E. (2003). "Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases". Neuromolecular medicine 4 (1-2): 21-36
Xu Y., Xiao G., Liu L., Lang M. (Dec 2019). "Zinc transporters in Alzheimer's disease". Molecular brain 12 (1): 10.1186/s13041-019-0528-2 .
Olsson B., Lautner R., Andreasson U., Öhrfelt A., Portelius E., Bjerke M., Hölttä M., Rosén C., Olsson C., Strobel G., Wu E., Dakin K., Petzold M., Blennow K., Zetterberg H. (2016). "CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis". The Lancet. Neurology 15 (7): 673-84 .
Jack C. R. Jr., Bennett D. A., Blennow K., Carrillo M. C., Dunn B., Haeberlein S. B., Holtzman D. M., Jagust W., Jessen F., et al. (2018). "NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease". Alzheimer's & dementia 14 (4): 535-62
Dubois B., Feldman H. H., et al. (Iun 2014). "Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria". The Lancet. Neurology 13 (6): 614-29 .

stetoskop.info

"Dementia in morbo Alzheimer . . . praecox . . . tardiva [etc.]": vide F00-F09 apud Stetoskop

web.archive.org

Vel "morbus Alzheimerianus," in Tuomo Pekkanen, "De morbo Alzheimeriano," Nuntii Latini, 26 Iulii 2002.